medigraphic.com
Colegio de Medicina Interna de México.

2021, Number 4

<< Back Next >>

Med Int Mex 2021; 37 (4)

Clinical and sociodemographic profile of Sjögren syndrome in a university hospital in Colombia

Moreno-Useche LD, Rangel-Rivera DA, Rangel-Rivera KL, Palmezano-Díaz JM, Salazar-Flórez JC

Language: Spanish
References: 31
Page: 520-528
PDF size: 258.95 Kb.


ABSTRACT

Objective: To analyze the clinical and sociodemographic manifestations in patients with Sjӧgren syndrome who were treated at the University Hospital of Santander.
Materials and Methods: A retrospective cross-sectional descriptive study. The study population was integrated by patients older than 13 years who entered to University Hospital of Santander in Colombia from 2012 to 2016. Patients who did not have a complete and detailed medical history were excluded.
Results: Were analyzed 45 patients with Sjӧgren syndrome, we got a prevalence of 12/100,000 patients; 41 were women. The average age in the cases was 55.4 years. The median of evolution time of the symptoms was of 48 months. All the patients were caught in the outpatient consultant. Xerostomia was the clinical manifestation most frequently found, followed by the absence of saliva lake; in lesser frequency the ophthalmic disease, while only 6 cases presented Raynaud’s phenomenon; 40 out of 45 patients had another systemic disease, 19 of them had rheumatoid arthritis.
Conclusions: The prevalence of Sjӧgren syndrome in our study was lesser than the current literature; the gender ratio remained similar to other studies.


REFERENCES

  1. Rischmueller M, Tieu J, Lester S. Primary Sjögren’s syndrome. Best Pract Res Clin Rheumatol 2016; 30 (1): 189-220. doi.: 10.1016/j.berh.2016.04.003.

  2. Vivino FB. Sjögren’s syndrome: Clinical aspects. Clin Immunol 2017; 182: 48-54. doi. 10.1016/j.clim.2017.04.005.

  3. Fox RI. Sjögren’s syndrome. Lancet 2005; 366 (9482): 321- 31. doi. 10.1016/S0140-6736(05)66990-5.

  4. Amador-Patarroyo MJ, Arbelaez JG, Mantilla RD, Rodriguez- Rodriguez A, et al. Sjögren’s syndrome at the crossroad of polyautoimmunity. J Autoimmun 2012; 39(3): 199-205. doi. 10.1016/j.jaut.2012.05.008.

  5. Brito-Zerón P, Theander E, Baldini C, Seror R, et al. Early diagnosis of primary Sjögren’s syndrome: EULAR-SS task force clinical recommendations. Expert Rev Clin Immunol 2016; 12(2): 137-56. doi. 10.1586/1744666X.2016.1109449.

  6. Yamamoto M, Takahashi H, Sugai S, Imai K. Clinical and pathological characteristics of Mikulicz’s disease (IgG4- related plasmacytic exocrinopathy). Autoimmun Rev 2005; 4 (4): 195-200. doi. 10.1016/j.autrev.2004.10.005.

  7. Luciano N, Valentini V, Calabro A, Elefante E, et al. One year in review 2015: Sjögren’s syndrome. Clin Exp Rheumatol 2015; 33 (2): 259-71.

  8. Vitali C, Bombardieri S, Jonsson R, Moutsopoulos HM, et al. Classification criteria for Sjögren’s syndrome: a revised version of the European criteria proposed by the American- European Consensus Group. Ann Rheum Dis. 2002; 61 (6): 554-8. doi. 10.1136/ard.61.6.554.

  9. Mcmahon T, van Zijl PCM, Gilad AA. NIH Public Access. 2015; 27(3): 320-31.

  10. Barone F, Colafrancesco S. Sjögren’s syndrome: From pathogenesis to novel therapeutic targets. Clin Exp Rheumatol 2016; 34: 58-62.

  11. Reed JH, Jackson MW, Gordon TP. B cell apotopes of the 60- kDa Ro/SSA and La/SSB autoantigens. J Autoimmun 2008; 31 (3): 263-7. doi. 10.1016/j.jaut.2008.04.008.

  12. Theander E, Jonsson R, Sjöström B, Brokstad K, et al. Prediction of Sjögren’s syndrome years before diagnosis and identification of patients with early onset and severe disease course by autoantibody profiling. Arthritis Rheumatol 2015; 67 (9): 2427-36. doi. 10.1002/art.39214.

  13. Qin B, Wang J, Yang Z, Yang M, et al. Epidemiology of primary Sjögren’s syndrome: a systematic review and meta-analysis. Ann Rheum Dis 2015; 74 (11): 1983-9. doi. 10.1136/annrheumdis-2014-205375.

  14. Alamanos Y, Tsifetaki N, Voulgari PV, Venetsanopoulou AI, et al. Epidemiology of primary Sjögren’s syndrome in north-west Greece, 1982-2003. Rheumatology 2006; 45 (2): 187-91. doi. 10.1093/rheumatology/kei107.

  15. Weng MY, Huang YT, Liu MF, Lu TH. Incidence and mortality of treated primary Sjogren’s Syndrome in Taiwan: A Population-based Study. J Rheumatol 2011; 38 (4): 706-8. doi. 10.3899/jrheum.100883.

  16. Liang Y, Yang Z, Qin B, Zhong R. Primary Sjögren’s syndrome and malignancy risk: a systematic review and metaanalysis. Ann Rheum Dis 2014; 73 (6): 1151-6. doi. 10.1136/ annrheumdis-2013-203305.

  17. Lazarus MN, Isenberg DA. Development of additional autoimmune diseases in a population of patients with primary Sjögren’s syndrome. Ann Rheum Dis. 2005; 64 (7):1062-4. doi. 10.1136/ard.2004.029066.

  18. Kawashima K, Yoshino S. [Differences in the clinical feature of Sjögren’s syndrome in the presence and absence of rheumatoid arthritis]. Nihon Ika Daigaku Zasshi 1989; 56 (1): 31-8. doi. 10.1272/jnms1923.56.31.

  19. Ramos-Casals M, Brito-Zerón P, Seror R, Bootsma H, et al. Corrigendum: Characterization of systemic disease in primary Sjögren’s syndrome: EULAR-SS Task Force recommendations for articular, cutaneous, pulmonary and renal involvements. Rheumatology 2015; 54: 2230-2238. doi. 10.1093/rheumatology/kev200.

  20. Ramos-Casal M, Tzioufas AG, Font J. Primary Sjögren’s syndrome: New clinical and therapeutic concepts. Ann Rheum Dis. 2005; 64 (3): 347-54. doi. 10.1136/ard.2004.025676.

  21. Lockshin MD, Levine AB, Erkan D. Patients with overlap autoimmune disease differ from those with “pure” disease. Lupus Sci Med 2015; 2 (1): e000084-e000084. doi. 10.1136/ lupus-2015-000084.

  22. Uhlig T, Kvien TK, Jensen JL, Axéll T. Sicca symptoms, saliva and tear production, and disease variables in 636 patients with rheumatoid arthritis. Ann Rheum Dis 1999; 58 (7): 415-22. doi. 10.1136/ard.58.7.415.

  23. Gottenberg JE, Mignot S, Nicaise-Rolland P, Cohen-Solal J. Prevalence of anti-cyclic citrullinated peptide and antikeratin antibodies in patients with primary Sjögren’s syndrome. Ann Rheum Dis 2005; 64 (1): 114-7. doi. 10.1136/ ard.2003.019794.

  24. Payet J, Belkhir R, Gottenberg JE, Bergé E, et al. ACPA-positive primary Sjögren’s syndrome: true primary or rheumatoid arthritis-associated Sjögren’s syndrome? RMD Open 2015; 1 (1): e000066. doi. 10.1136/rmdopen-2015-000066.

  25. Nardi N, Brito-Zerón P, Ramos-Casals M, Aguiló S, et al. Circulating auto-antibodies against nuclear and non-nuclear antigens in primary Sjögren’s syndrome. Clin Rheumatol 2006; 25 (3): 341-6. doi. 10.1007/s10067-005-0059-3.

  26. Salemi S, Aeschlimann A, Gay RE, Michel BA, et al. Expression and localization of opioid receptors in muscle satellite cells: No difference between fibromyalgia patients and healthy subjects. Arthritis Rheum 2003; 48 (11): 3291-3. doi. 10.1002/art.11312.

  27. Rischmueller M, Lester S, Chen Z, Champion G, et al. HLA class II phenotype controls diversification of the autoantibody response in primary Sjögren’s syndrome (pSS). Clin Exp Immunol 1998; 111 (2): 365-71. doi. 10.1046/j.1365- 2249.1998.00504.x.

  28. Foulks GN, Forstot SL, Donshik PC, Forstot JZ, et al. Clinical guidelines for management of dry eye associated with Sjögren’s disease. Ocul Surf 2015; 13 (2): 118-32. doi. 10.1016/j.jtos.2014.12.001.

  29. Tsifetaki N, Kitsos G, Paschides CA, Alamanos Y, et al. Oral pilocarpine for the treatment of ocular symptoms in patients with Sjögren’s syndrome: a randomised 12 week controlled study. Ann Rheum Dis 2003; 62 (12): 1204-7. doi. 10.1136/ard.2002.003889.

  30. Saraux A, Pers JO, Devauchelle-Pensec V. Treatment of primary Sjögren syndrome. Nat Rev Rheumatol 2016; 12 (8): 456-71. doi. 10.1038/nrrheum.2016.100.

  31. Gottenberg JE, Ravaud P, Puéchal X, Le Guern V, et al. Effects of Hydroxychloroquine on Symptomatic Improvement in Primary Sjögren Syndrome. JAMA 2014; 312 (3): 249. doi. 10.1001/jama.2014.7682.




2020     |     www.medigraphic.com